BioLife (BLFS) Rule 144 Notice Shows 500k-Share Sale via BMO

Rhea-AI Filing Summary

BioLife Solutions, Inc. (BLFS) Rule 144 notice reports a proposed sale of 500,000 common shares through BMO Capital Markets on 08/15/2025 with an aggregate market value of $12,660,000. The filing states total shares outstanding of 47,905,265. The securities to be sold were acquired in three cash purchases: 250,000 on 07/02/2020, 100,000 on 12/16/2020, and 150,000 on 04/30/2024. The filer discloses prior sales by Casdin Partners Master Fund, L.P.: 1,000,000 shares on 06/10/2025 and 500,000 shares on 08/11/2025 with stated gross proceeds.

Positive

• Planned sale fully disclosed: Broker, sale date, quantity, and aggregate market value are provided
• Acquisition history given: Purchase dates and cash payment method for the shares being sold are listed

Negative

• Large recent dispositions: Casdin Partners sold 1,500,000 shares in the past months, which may increase share supply
• No issuer financial context: The filing contains no operational or performance data about the company

Insights

Securities Analyst

TL;DR: Routine Rule 144 notice disclosing a 500,000-share proposed sale and recent large dispositions by the same holder.

The filing is a standard Rule 144 notification identifying the broker, planned sale date, and acquisition history for the shares being offered. It confirms the seller's representation that no undisclosed material adverse information is known. The filing also records two recent completed sales by Casdin Partners Master Fund, L.P. totaling 1.5 million shares, with stated gross proceeds, which is relevant to supply dynamics but is presented here as disclosure rather than commentary.

Corporate Governance Specialist

TL;DR: Disclosure meets regulatory requirements; shows transparent reporting of acquisition dates and prior disposals.

The notice lists acquisition dates, payment method (cash), and the broker handling the proposed transaction, satisfying Rule 144 disclosure elements. The signer affirms absence of undisclosed material adverse information. There is no additional corporate or financial detail in this filing to suggest change in issuer governance or strategy.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock, par value $0.001 per share	BMO Capital Markets 151 W 42nd St New York NY 10036	500000	12660000.00	47905265	08/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock, par value $0.001 per share	07/02/2020	Purchase	The shares were purchased directly from the issuer.			250000	07/02/2020	Cash
Common Stock, par value $0.001 per share	12/16/2020	Purchase	The shares were purchased directly from a shareholder of the issuer.			100000	12/16/2020	Cash
Common Stock, par value $0.001 per share	04/30/2024	Purchase	The shares were purchased directly from a shareholder of the issuer.			150000	04/30/2024	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Casdin Partners Master Fund, L.P. 1350 Avenue of the Americas Suite 2600 New York NY 10019	Common Stock, par value $0.001 per share	08/11/2025	500000	11300000.00
Casdin Partners Master Fund, L.P. 1350 Avenue of the Americas Suite 2600 New York NY 10019	Common Stock, par value $0.001 per share	06/10/2025	1000000	23800000.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for BLFS disclose?

The form discloses a proposed sale of 500,000 BLFS common shares via BMO Capital Markets on 08/15/2025 with an aggregate market value of $12,660,000.

How many BLFS shares are outstanding per the filing?

The filing reports 47,905,265 shares outstanding.

When were the shares being offered acquired?

The offered shares were acquired in cash on 07/02/2020 (250,000), 12/16/2020 (100,000), and 04/30/2024 (150,000).

Has the seller recently sold BLFS shares?

Yes. The filing lists prior sales by Casdin Partners Master Fund, L.P.: 1,000,000 shares on 06/10/2025 (gross proceeds $23,800,000) and 500,000 shares on 08/11/2025 (gross proceeds $11,300,000).

Who is the broker handling the proposed sale?

The broker named is BMO Capital Markets, located at 151 W 42nd St, New York, NY.